Vesugen Peptide: Dosage and Treatment Information
Critical Evidence Gap
There are no established FDA-approved dosing protocols or treatment cycles for Vesugen (Lys-Glu-Asp tripeptide), as this peptide lacks regulatory approval for clinical use in the United States or other major regulatory jurisdictions. The available evidence consists solely of small Russian research studies with significant methodological limitations and no standardized dosing recommendations 1, 2, 3, 4.
Available Research Data (Non-Standardized)
Study-Reported Dosing Patterns
The limited published research on Vesugen provides only fragmentary dosing information:
Erectile dysfunction study: 41 patients received Vesugen monotherapy for vasculogenic erectile dysfunction, but the specific dose, frequency, duration, and route of administration were not reported in the published abstract 1.
Aging/polymorbidity study: 32 patients (ages 41-83 years) with chronic polymorbidity received Vesugen, but again no specific dosing regimen, treatment duration, or administration route was documented 2.
Cell culture studies: In vitro experiments used Vesugen to stimulate vascular endothelial cell proliferation, but these laboratory concentrations cannot be extrapolated to human dosing 3, 4.
Route of Administration
The research suggests subcutaneous or intradermal injection as the likely route based on the study contexts, but this is not explicitly stated in any publication 1, 2.
Critical Safety Concerns
Lack of Safety Data
No toxicity studies: There are no published dose-ranging studies, maximum tolerated dose evaluations, or systematic adverse event reporting 1, 2.
Prooxidant activity: One study detected prooxidant activity through chemiluminescence testing, raising concerns about oxidative stress induction 2.
Hematopoietic suppression: Decreased CD34+ hematopoietic stem cells were observed, indicating potential bone marrow suppression effects 2.
Unknown drug interactions: No studies have evaluated interactions with common medications used in elderly or polymorbid patients 2.
Regulatory Status
Not FDA-approved: Vesugen has no approval from the FDA, EMA, or other major regulatory bodies for any indication 5.
No quality control standards: Without regulatory oversight, there are no established purity standards, manufacturing requirements, or batch-to-batch consistency guarantees 5, 6.
Clinical Recommendation
I cannot recommend specific dosing or treatment cycles for Vesugen peptide because no evidence-based protocols exist, and the safety profile remains inadequately characterized. The available literature consists of small, poorly documented Russian studies that fail to meet basic standards for clinical trial reporting 1, 2, 3, 4.
Why This Matters for Patient Safety
Peptide stability issues: Therapeutic peptides generally suffer from poor metabolic stability and short half-lives, requiring careful formulation and dosing strategies that have not been established for Vesugen 6.
Individual variability: Without pharmacokinetic data, there is no way to predict appropriate dosing for different patient populations, body weights, or disease states 5, 6.
Lack of efficacy benchmarks: No validated outcome measures or treatment response criteria exist to guide therapy duration or dose adjustments 1, 2.
Alternative Considerations
For vascular health and endothelial function, evidence-based interventions with established safety profiles should be prioritized over experimental peptides with inadequate clinical validation 1, 5.